FOR IMMEDIATE RELEASE CONTACT: Leigh Ann Bradley July 18, 2011 703-548-0019
Patient Advocate FoundationAnnounces the Launch of Two New Support Categories within Their Co-Pay Relief Program: Assistance Now Available for Patients Receiving Hormone Suppression Therapy and Those withNon-Muscle Invasive Bladder Cancer
Co-Pay Relief Program Provides Direct Financial Support for Pharmaceutical Co-Payments to Insured Patients in Medical and Financial Need
HAMPTON, VA (July 18, 2011) –Patient Advocate Foundation (PAF), a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases,is pleased to announce that it has received funding support for patients with non-muscle invasive bladder cancer and those being treated with hormone suppression therapy through its Co-Pay Relief Program (CPR).
PAF’s Co-Pay Relief Program provides direct financial support for pharmaceutical co-payments to insured patients, including Medicare Part D beneficiaries, who financially and medically qualify. CPR has three entry points and handles more than 120,000 expenditure transactions per year. Since the program’s inception in April 2004, CPRhas allocated more than $120 million dollars in patient assistance to more than 45,800 patients nationwide; mobilizing $480 million dollars in insurance reimbursement.
“Patient Advocate Foundation is committed to improving the quality of life of patients facing medical and financial hardship through our professional case management and Co-Pay Relief services. We are excited to announce this new funding for our Co-Pay Relief Program, which will now allow us to offer financial assistance to non-muscle invasive bladder cancer and hormone suppression therapy patients across the nation,” said Nancy Davenport-Ennis, Founder and CEO of PAF.
“A debilitating or life-threatening diagnosis can be the most overwhelming experience a person may ever face in his or her lifetime. Coupled with high-cost pharmaceutical co-pay expenses, the journey can become significantly more challenging to manage,” Davenport-Ennis said. “Patient Advocate Foundation created the Co-Pay Relief Program in 2004 after receiving an increased number of patients seeking co-pay assistance for pharmaceutical drugs, so we are particularly pleased to be able to offer assistance to more patients every year.”
Patient Advocate Foundation and its companion organization, the National Patient Advocate Foundation (NPAF), were founded on the principle that health care is a basic human need and shared social responsibility. Annually, PAF receivesthousands of contacts requesting information and assistance via their toll-free hotline, as well as online, with complete direct, sustained case management services provided to patients from all fifty states free of charge. For more information about PAF, visit or call toll free (800) 532-5274. For more information about PAF’s Co-Pay Relief Program visit or call toll free (866) 512-3861.
###